Aerovate Therapeutics Quarterly Income Statements Chart
Quarterly
|
Annual
Aerovate Therapeutics Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| operating expenses: | |||||||||||||||||
| research and development | 22,547,000 | 1,531,000 | 10,328,000 | 21,248,000 | 20,080,000 | 17,813,000 | 16,884,000 | 16,034,000 | 13,488,000 | 12,221,000 | 10,783,000 | 8,363,000 | 7,255,000 | 11,569,000 | 3,418,000 | 4,327,000 | |
| general and administrative | 5,231,000 | 3,387,000 | 4,872,000 | 7,082,000 | 4,917,000 | 4,538,000 | 4,253,000 | 4,484,000 | 4,302,000 | 4,151,000 | 3,631,000 | 3,369,000 | 3,852,000 | 3,764,000 | 5,253,000 | 2,782,000 | 1,447,000 |
| total operating expenses | 27,778,000 | 3,387,000 | 6,403,000 | 17,410,000 | 26,165,000 | 24,618,000 | 22,066,000 | 21,368,000 | 20,336,000 | 17,639,000 | 15,852,000 | 14,152,000 | 12,215,000 | 11,019,000 | 16,822,000 | 6,200,000 | 5,774,000 |
| income from operations | -27,778,000 | -3,387,000 | -6,403,000 | -17,410,000 | -26,165,000 | -24,618,000 | -22,066,000 | -21,368,000 | -20,336,000 | -17,639,000 | -15,852,000 | -14,152,000 | -12,215,000 | -11,019,000 | -16,822,000 | -6,200,000 | -5,774,000 |
| yoy | 6.16% | -86.24% | -70.98% | -18.52% | 28.66% | 39.57% | 39.20% | 50.99% | 66.48% | 60.08% | -5.77% | 128.26% | 111.55% | ||||
| qoq | 720.14% | -47.10% | -63.22% | -33.46% | 6.28% | 11.57% | 3.27% | 5.07% | 15.29% | 11.27% | 12.01% | 15.86% | 10.85% | -34.50% | 171.32% | 7.38% | |
| operating margin % | |||||||||||||||||
| other income: | -2,000 | -10,000 | -6,000 | -3,000 | 1,000 | ||||||||||||
| interest income | 1,828,000 | 871,000 | 1,028,000 | 1,183,000 | 1,396,000 | 1,435,000 | 1,709,000 | 1,804,000 | 1,312,000 | 1,120,000 | 932,000 | 560,000 | 230,000 | 109,000 | 49,000 | 16,000 | 2,000 |
| change in fair value of convertible notes payable | -6,184,000 | ||||||||||||||||
| total other income | -4,356,000 | 869,000 | 1,028,000 | 1,173,000 | 1,390,000 | 1,432,000 | 1,709,000 | 1,805,000 | 1,311,000 | 1,119,000 | 855,000 | 564,000 | 224,000 | 109,000 | 46,000 | 16,000 | -1,000 |
| net income | -32,134,000 | -2,518,000 | -5,430,000 | -16,237,000 | -24,775,000 | -23,186,000 | -20,413,000 | -19,563,000 | -19,025,000 | -16,520,000 | -15,022,000 | -13,588,000 | -11,991,000 | -10,910,000 | |||
| yoy | 29.70% | -89.14% | -73.40% | -17.00% | 30.22% | 40.35% | 35.89% | 43.97% | 58.66% | 51.42% | |||||||
| qoq | 1176.17% | -53.63% | -66.56% | -34.46% | 6.85% | 13.58% | 4.34% | 2.83% | 15.16% | 9.97% | 10.55% | 13.32% | 9.91% | ||||
| net income margin % | |||||||||||||||||
| other comprehensive loss: | |||||||||||||||||
| currency translation adjustment | -24,000 | ||||||||||||||||
| comprehensive loss | -32,158,000 | -2,573,000 | -5,549,000 | -15,930,000 | -24,825,000 | -23,456,000 | -19,953,000 | -19,585,000 | -19,047,000 | -16,255,000 | -14,717,000 | -13,574,000 | -12,132,000 | -11,495,000 | |||
| net income per share | -0.86 | -0.09 | -0.19 | -0.56 | -0.86 | -0.83 | -0.74 | -0.71 | -0.76 | -0.67 | -0.61 | -0.56 | -0.49 | -0.45 | -1.61 | -0.26 | -23.8 |
| weighted-average shares used for eps calculation | 28,431,158 | ||||||||||||||||
| comprehensive loss: | |||||||||||||||||
| unrealized gain on securities | -55,000 | -119,000 | 307,000 | -50,000 | -270,000 | 460,000 | -22,000 | -22,000 | 265,000 | -178,000 | 14,000 | ||||||
| weighted-average shares of common stock outstanding, basic and diluted | 28,985,019 | 28,582,194 | 28,863,327 | 28,756,043 | 27,795,827 | 26,331,630 | 27,640,542 | 25,166,505 | 24,777,847 | 24,472,104 | 24,454,786 | 24,410,503 | 24,410,393 | 12,293,629 | 23,885,017 | 243,076 | |
| other income | -1,000 | -1,000 | -77,000 | 4,000 | -6,000 | -3,000 | |||||||||||
| unrealized loss on securities | -141,000 | ||||||||||||||||
| net income before income taxes | -10,910,000 | ||||||||||||||||
| unrealized loss on available-for-sale investments | -585,000 | ||||||||||||||||
| change in fair value of convertible promissory notes | |||||||||||||||||
| net income and comprehensive loss | -1,546,000 | -6,184,000 | -5,775,000 | ||||||||||||||
| |
We provide you with 20 years income statements for Aerovate Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Aerovate Therapeutics stock. Explore the full financial landscape of Aerovate Therapeutics stock with our expertly curated income statements.
The information provided in this report about Aerovate Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.